Postmarketing surveillance study of asciminib in patients with resistant/intolerant chronic myeloid leukemia in Japan
rates by week 48 were 42.3% and 26.5%, respectively, with some patients harboring baseline BCR::ABL1 mutations showing these responses. These real-world outcomes support the safety and effectiveness of asciminib for patients with resistant/intolerant CML.
Authors
- Kazuaki Yamaguchi
- Makoto Aoki
Institutions
- Novartis (Japan) (JP)
- Toranomon Hospital (JP)
Publication Details
- Journal
- International Journal of Hematology
- Published
- 2026-03-31
- DOI
- https://doi.org/10.1007/s12185-026-04199-x
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharma
- Novartis Pharmaceuticals UK Limited
- Novartis Japan